FDA Brief

Warning letters Biologics

FDA warning letter to

Estar Technologies Ltd

High riskIssued Apr 22Posted May 12Center for Biologics Evaluation and Research

FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

What happened

FDA found the issue by reviewing Estar's websites, tropocells.com and estar-medical.com, in April 2026. FDA said the firm was offering seven PRP/PRF device kits for sale in the U.S. without premarket approval (PMA) or an investigational device exemption (IDE — permission to study an unapproved device in humans). FDA also said website claims for the Tropocells PRP kit go beyond its cleared 510(k) (premarket notification) indication and require a new notification.

What FDA found

  1. Estar offered seven PRP/PRF device kits for sale in the U.S. without FDA premarket approval (PMA) or an approved investigational device exemption (IDE).

    Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  2. Estar did not notify FDA before commercially distributing the devices, as required by the 510(k) premarket notification process.

    Section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)
  3. Estar's website claims for the Tropocells PRP kit expand its use beyond the cleared indication, a major change that requires a new 510(k) notification.

    21 CFR 807.81(a)(3)
  4. Introducing these illegally marketed devices — called adulterated or misbranded — into interstate commerce is a prohibited act.

    Section 301(a), 21 U.S.C. § 331(a)

What FDA wants

FDA tells Estar to stop activities that make the devices misbranded or adulterated, including commercial distribution for the cited uses. Estar must answer in writing within 15 business days with the steps taken, supporting documents, and a timetable for any work not finished.

Who should pay attention

  • U.S. clinics and clinicians considering PRP/PRF kits for unapproved uses
  • distributors and importers of Estar or similar PRP/PRF devices
  • manufacturers relying on a limited 510(k) clearance while marketing broader indications

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  4. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk